Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2017

  • KMI-73263
  • Jul 2017
  • 72 pages
  • Healthcare
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2017

Summary

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Pipeline Review, H2 2017, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Neuronal acetylcholine receptor subunit alpha-7 is a protein encoded by the CHRNA7 gene. After binding to acetylcholine it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 5, 4 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Central Nervous System and Metabolic Disorders which include indications Alzheimer's Disease, Cognitive Impairment Associated With Schizophrenia (CIAS), Schizophrenia, Attention Deficit Hyperactivity Disorder (ADHD), Bipolar Disorder (Manic Depression), Cognitive Disorders, Cognitive Impairment, Parkinson's Disease, Smoking Addiction, Chronic Pain, Complex Regional Pain Syndrome, Dementia Associated With Alzheimer's Disease, Generalized Anxiety Disorder (GAD), Major Depressive Disorder, Neurodegenerative Diseases, Neuropathic Pain, Obesity, Pain, Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury.

Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)
- The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects
- The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Overview
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Companies Involved in Therapeutics Development
Bionomics Ltd
Bristol-Myers Squibb Company
CoMentis Inc
Johnson & Johnson
Merck & Co Inc
NeuroDerm Ltd
Saniona AB
SK Biopharmaceuticals Co Ltd
Vanda Pharmaceuticals Inc
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Drug Profiles
(nicotine + opipramol hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AN-761 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQW-051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVL-3288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVL-8168 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-910731 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-375 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gln-1062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GTS-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-39393406 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NBP-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKLA-4R - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Alpha-7 Nicotinic Acetylcholine Receptor for Alzheimer’s Disease and Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize CHRNA7 for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Activate Neuronal Acetylcholine Receptor Subunit Alpha-7 for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Dormant Products
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Discontinued Products
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Product Development Milestones
Featured News & Press Releases
Jun 15, 2017: Bionomics Invited to PTSD State of the Science Summit to Present Key BNC210 Data
May 18, 2017: Expanded BNC210 Clinical Data to be Presented at US Psychiatry Convention
Feb 03, 2017: Bionomics to Receive Milestone Payment from MSD for Initiation of Phase 1 Clinical Study of Candidate Alzheimer's Treatment
Jan 09, 2017: Bionomics Provides Update on BNC-210 Clinical Program At 2017 San Francisco Biotech Showcase
Sep 21, 2016: Bionomics Announces Positive Results from Phase 2 Trial of BNC210 in Generalized Anxiety Disorder
Sep 16, 2016: Bionomics to present anti-anxiety drug treatment trial results and ADHD treatment research at ECNP
Jun 30, 2016: Bionomics To Trial Drug Against Post-Traumatic Stress Disorder
Jun 24, 2016: Enrolment Completed in BNC210 Generalised Anxiety Disorder Trial
Mar 29, 2016: Neurodyn Cognition to Present Memogain Clinical Developments at Neurotech Investing and Partnering Conference
Dec 08, 2015: Post Traumatic Stress Disorder Identified as Major New Market Opportunity for BNC210
Sep 16, 2015: Bionomics Reports Positive Data from Phase 1 Multiple Ascending Dose Trial of BNC210 for Anxiety and Depression
Apr 20, 2015: Bionomics Initiates Phase II Clinical Trial Of BNC210 For Treatment Of Anxiety
Feb 02, 2015: Bionomics Begins Phase 1b Study With Anxiety Drug Bnc210
Nov 17, 2014: Bionomics to Present BNC210 at Society for Neuroscience Meeting
Nov 11, 2014: Bionomics to Progress BNC210 in Clinical Trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

   Global Healthcare IT Consulting Market By Type (Strategy, Project Management, Integration, Migration, Security, Risk assessment, Analytics, BPM, Regulatory), End User (Hospitals, IDN, ACC, Home, Payer, Public, Private) and Region (North America, Asia Pacific, Europe, Latin America, Rest of the World) Market Size, Status and Forecast to 2025

   Global Life Science Analytics Market By Type (Descriptive, Prescriptive), Application (Marketing, Compliance, R&D, SCM), Component (Software, Service), Delivery (on premise, cloud) and End user (Pharmaceutical, Biotechnology, Medical Device, CRO), and Region (North America, Asia Pacific, Europe, Latin America, Rest of the World) Market Size, Status and Forecast to 2025

   Global ECG Cable and ECG Lead wires Market By Material (Thermoplastic Elastomer, TPU), Usability (Reusable, Disposable), ECG Lead wires by Machine Type (3 lead, 5 lead), Patient Care Setting (Long term care facilities, Home care) and Regional Market Size, Status and Forecast to 2025

   Global Defibrillators Market By Product (Implantable Cardioverter Defibrillator (Transvenous ICD, Single & Dual Chamber, CRT-D, S-ICD) and External (Manual, AED, Wearable)), End User (Hospital, Prehospital, Public Access, Home) and Regional Market Size, Status and Forecast to 2025

   Global Cardiac Marker Testing Market By Type (Troponin I & T, CK-MB, Myoglobin, BNP, hsCRP), Product (Reagent, Instrument), Method (Chemi-luminescence, ELISA), Disease (Myocardial Infarction, Congestive Heart Failure), Testing (Lab, POC) and Regional Market Size, Status and Forecast to 2025

   Global Atrial Fibrillation Surgery Market By Procedure (Catheter Ablation, Surgical Ablation/Maze), Product (Catheter Ablation, Surgical Ablation), and Geography (Canada, China, France, Germany, India, Japan, U.S., U.K.) and Regional Market Size, Status and Forecast to 2025

   Global Anatomic Pathology Market By Product & Service (Instruments (Tissue Processing Systems, Microtome), Consumables (Reagent & Antibodies), Histopathology, Cytopathology), Application (Disease Diagnosis, Drug Discovery & Development) and Regional Market Size, Status and Forecast to 2025

   Global Blood Group Typing Market By Product (Consumable (Anti-sera), Instrument, Service), Test Type (ABO, Antigen, Antibody Screening, Cross Matching, HLA), Technique (Assay, PCR, Microarray, Massively Parallel Sequencing), End User and Regional Market Size, Status and Forecast to 2025

   Global Healthcare Mobility Solutions Market By Products & Services (Mobile Devices, Mobile Apps, Enterprise Platforms), Application (Patient Care, Operations, Workforce Management), End User (Payers, Providers, Patients) and Regional Market Size, Status and Forecast to 2025

   Global Pharmacovigilance and Drug Safety Software Market By Source (Whole Grain Products, Fruits & Vegetables, Others), Product (Soluble Dietary Fibers, Insoluble Dietary Fibers), Application (Food, Beverages, Pharmaceuticals, Others) and Regional Market Size, Status and Forecast to 2025

Purchase this Market Research Report



Contact Us


Mannan
Mannan Shaikh
Head-Sales
mansing
Mansingh Surve
Manager-Sales
Diksha
Diksha Singh Rathore
Team Lead-Sales
view